Mitchell Daniel, Yong Michelle, Raju Jyothy, Willemsen Nicole, Black Matthew, Trent Amanda, Tirrell Matthew, Olive Colleen
The Queensland Institute of Medical Research, Brisbane, Australia.
Hum Vaccin. 2011 Jan-Feb;7 Suppl:85-93. doi: 10.4161/hv.7.0.14567. Epub 2011 Jan 1.
Considerable success has been made with many peptide antigen formulations and it appears that peptide-based vaccines are emerging as the next generation of prophylactic and remedial immunotherapy. However, peptides are typically poorly immunogenic and rely on delivery with potent immunostimulatory adjuvants that activate the innate and adaptive arms of the immune system. Our research aims to develop novel peptide antigen delivery systems that incorporate multiple pattern-recognition receptor (PRR) agonists and is focused on those designed to stimulate Toll-like receptors (TLRs) on dendritic cells (DCs). The cytokine (IL-4, IL-6, IL-10, IL-12 and IL-23) profiles of DCs induced by individual TLR agonists have been evaluated. From this data we predicted which TLR agonists may influence a particular T helper cell (Th) response. Using purified DCs that were derived from precursor cells in murine bone marrow and then stimulated simultaneously with multiple TLR agonists, we have shown synergy between various TLR agonist pairs leading to enhanced cytokine production. Using various mitogen-activated protein kinase (MAPK) inhibitors (c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) and p38 MAPK) we have demonstrated the importance of p38 MAPK and ERK signaling pathways in IL-12p70 and IL-12p40 production in DCs induced by TLR stimulation, whereas the JNK pathway appeared to have a negative regulatory role on cytokine production in DCs stimulated with certain TLR agonists. An important role for nuclear factor-kappa B and phosphoinositol-3-kinase as positive regulators of TLR signaling in DCs leading to cytokine production was also demonstrated. The significance of this research lies not only in improving potency, but by understanding the immunological mechanisms of adjuvanticity, in being able to tailor peptide vaccines to generate specific types of Th responses required for immunity against various types of pathogens.
许多肽抗原制剂已取得了相当大的成功,基于肽的疫苗似乎正在成为下一代预防性和补救性免疫疗法。然而,肽通常免疫原性较差,依赖于与能激活免疫系统固有和适应性分支的强效免疫刺激佐剂一起递送。我们的研究旨在开发包含多种模式识别受体(PRR)激动剂的新型肽抗原递送系统,并专注于那些旨在刺激树突状细胞(DC)上的Toll样受体(TLR)的系统。已评估了由单个TLR激动剂诱导的DC的细胞因子(IL-4、IL-6、IL-10、IL-12和IL-23)谱。根据这些数据,我们预测了哪些TLR激动剂可能影响特定的辅助性T细胞(Th)反应。使用从小鼠骨髓中的前体细胞衍生而来,然后与多种TLR激动剂同时刺激的纯化DC,我们已经证明了各种TLR激动剂对之间的协同作用导致细胞因子产生增加。使用各种丝裂原活化蛋白激酶(MAPK)抑制剂(c-Jun氨基末端激酶(JNK)、细胞外信号调节激酶(ERK)和p38 MAPK),我们已经证明了p38 MAPK和ERK信号通路在TLR刺激诱导的DC中IL-12p70和IL-12p40产生中的重要性,而JNK途径似乎对某些TLR激动剂刺激的DC中的细胞因子产生具有负调节作用。还证明了核因子-κB和磷酸肌醇-3-激酶作为DC中TLR信号传导导致细胞因子产生的正调节剂的重要作用。这项研究的意义不仅在于提高效力,还在于通过了解佐剂作用的免疫机制,能够定制肽疫苗以产生针对各种病原体免疫所需的特定类型的Th反应。